Molecular Partners announces presentation of preclinical data at AACR

Molecular Partners (MOLN) announced the presentation of new preclinical data across three posters at the American Association for Cancer Research, AACR, Annual Meeting 2026. The first poster outlines preclinical data supporting proof-of-concept for MP0632, a logic-gated Switch-DARPin CD3 T cell engager with CD2 co-stimulation designed to selectively kill cells co-expressing mesothelin and epithelial cell adhesion molecule. MP0632 leads to regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tumors expressing only one antigen, indicating a favorable therapeutic window. In addition, the Switch-DARPin candidate allowed for safe use of potent costimulation for efficient tumor cell killing with low cytokine release profile. The data support MP0632’s potential as clinical lead candidate for the treatment of ovarian cancer and other MSLN- and EpCAM-positive solid tumors. The second poster presents a computational workflow to identify and prioritize tumor-associated antigen pairs for improved tumor-selectivity and safety in support of designing novel Switch-DARPin candidates, such as MP0632. This scalable, data-driven platform provides a strong foundation for the discovery of next-generation multispecific immunotherapies. The third poster outlines the molecular characteristics of MP0712, the Company’s first 212Pb-based Radio-DARPin candidate, with high affinity binding to DLL3 and optimized half-life extended properties.